Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
$2.82
-7.0%
$21.77
$0.51
$10.55
$20.92M0.933.15 million shs140,517 shs
Cerecor Inc. stock logo
CERC
Cerecor
$10.14
-4.8%
$2.60
$1.98
$4.50
$973.53M1.441.27 million shs187,458 shs
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$1.17
+2.6%
$1.37
$0.65
$15.25
$19.39M1.35468,046 shs181,776 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.25
+0.8%
$1.30
$1.13
$2.55
N/A0.4363,951 shs18,306 shs
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$1.76
$1.74
$1.47
$4.72
$279.84M0.47915,733 shs574,041 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00%-1.86%+226.06%+146.54%+69.88%
Cerecor Inc. stock logo
CERC
Cerecor
0.00%-8.15%+18.13%+131.13%+18.65%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-5.79%-6.56%-14.29%+33.60%-91.23%
MediciNova, Inc. stock logo
MNOV
MediciNova
+0.81%-1.59%-5.34%-1.59%-31.87%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-4.86%-1.68%+1.15%-37.14%-58.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
$2.82
-7.0%
$21.77
$0.51
$10.55
$20.92M0.933.15 million shs140,517 shs
Cerecor Inc. stock logo
CERC
Cerecor
$10.14
-4.8%
$2.60
$1.98
$4.50
$973.53M1.441.27 million shs187,458 shs
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$1.17
+2.6%
$1.37
$0.65
$15.25
$19.39M1.35468,046 shs181,776 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.25
+0.8%
$1.30
$1.13
$2.55
N/A0.4363,951 shs18,306 shs
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$1.76
$1.74
$1.47
$4.72
$279.84M0.47915,733 shs574,041 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00%-1.86%+226.06%+146.54%+69.88%
Cerecor Inc. stock logo
CERC
Cerecor
0.00%-8.15%+18.13%+131.13%+18.65%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-5.79%-6.56%-14.29%+33.60%-91.23%
MediciNova, Inc. stock logo
MNOV
MediciNova
+0.81%-1.59%-5.34%-1.59%-31.87%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-4.86%-1.68%+1.15%-37.14%-58.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00
N/AN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
0.00
N/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.50
Moderate Buy$53.004,429.91% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.00
Buy$7.00460.00% Upside
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
3.20
Buy$7.40320.45% Upside

Current Analyst Ratings Breakdown

Latest ANCN, CERC, MREO, CTXR, and MNOV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/27/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
8/25/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$7.00 ➝ $8.00
8/13/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$6.00
7/24/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
7/10/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$7.00 ➝ $5.00
6/30/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$6.00
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuyStrong-Buy$6.00 ➝ $5.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/A$2.01 per shareN/A
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M145.30N/AN/A$0.22 per share46.09
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$10.25 per shareN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$1MN/AN/AN/A$1.07 per shareN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$500K559.68N/AN/A$0.39 per share4.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
-$27.12M-$3.4618.80N/AN/AN/A36.08%27.40%N/A
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$39.14MN/A0.000.94N/AN/A-60.03%-33.83%N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$43.25M-$0.07N/AN/AN/AN/A-80.00%-66.94%11/11/2025 (Estimated)

Latest ANCN, CERC, MREO, CTXR, and MNOV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.07-$0.07N/A-$0.07N/A$0.14 million
8/12/2025Q3 2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$0.76-$0.80-$0.04-$0.80$1.92 million$1.92 million
8/12/2025Q2 2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$0.01-$0.02-$0.01-$0.02$7.80 million$0.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/A
3.25
3.25
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/A
0.47
0.14
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
13.26
13.26
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/A
8.13
8.13

Institutional Ownership

CompanyInstitutional Ownership
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
9.05%
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
62.83%

Insider Ownership

CompanyInsider Ownership
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
6.88%
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
10.70%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
5.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
167.42 millionN/ANot Optionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2017.01 million15.19 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
10N/AN/AOptionable
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
40159.00 million150.26 millionOptionable

Recent News About These Companies

Analysts Offer Predictions for MREO Q1 Earnings
Analysts Set Expectations for MREO Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anchiano Therapeutics stock logo

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Cerecor stock logo

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$1.17 +0.03 (+2.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.18 +0.01 (+0.85%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.25 +0.01 (+0.81%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 0.00 (-0.40%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Mereo BioPharma Group stock logo

Mereo BioPharma Group NASDAQ:MREO

$1.76 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 +0.01 (+0.85%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.